Holen Sie sich die Stockscreener-App
1.08
0.94%
0.02
Handel nachbörslich:
1.07
-0.01
-0.93%
Schlusskurs vom Vortag:
$1.06
Offen:
$1.05
24-Stunden-Volumen:
507.01K
Relative Volume:
0.61
Marktkapitalisierung:
$70.58M
Einnahmen:
$9.14M
Nettoeinkommen (Verlust:
$-124.31M
KGV:
-1.1282
EPS:
-0.9573
Netto-Cashflow:
$-125.43M
1W Leistung:
+11.10%
1M Leistung:
-15.08%
6M Leistung:
-3.60%
1J Leistung:
-22.46%
1-Tages-Spanne:
$1.04
$1.08
1-Wochen-Bereich:
$0.96
$1.08
52-Wochen-Spanne:
$0.8824
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.08 | 69.27M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
TScan Therapeutics Q1 2026 Earnings: Narrowing Loss Despite EPS Miss, Stock Gains on Pipeline ProgressUpward Estimate Revision - Newser
TScan Therapeutics Expands Authorized Shares After Stockholder Vote - TipRanks
TScan Therapeutics Analyst Ratings and Price Targets | NASDAQ:TCRX - Benzinga
TScan Therapeutics (TCRX) director granted stock options for 67,000 shares - Stock Titan
Baker-linked TScan (TCRX) director granted 67,000 stock options - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) wins vote to double authorized common stock - Stock Titan
TScan Therapeutics (TCRX) director awarded 67,000 stock options at $0.9946 - Stock Titan
Director at TScan Therapeutics (NASDAQ: TCRX) granted 67,000 options - Stock Titan
TScan Therapeutics (TCRX) director receives 67,000 stock option grant - Stock Titan
TScan Therapeutics (TCRX) director granted stock options on 67,000 shares - Stock Titan
TScan Therapeutics (TCRX) Stock Analysis: +3.27% Gain — What to Watch 2026-05-20Low Volatility Picks - Newser
TScan Therapeutics (TCRX) Q1 2026 Earnings Miss by Significant: Key TakeawaysUpward Estimate Revision - Newser
TScan Therapeutics, Inc.Common Stock (NQ: TCRX - FinancialContent
BVF group reports near‑10% stake in TScan Therapeutics (NASDAQ: TCRX) - Stock Titan
TradingKey - TradingKey
TCRX SEC FilingsTscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
The fundamentals driving TScan Therapeutics (TCRX) everyone should understand (Under Pressure) 2026-05-08Institutional Buying - newser.com
Wedbush Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained - TipRanks
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Black Hills Pioneer
TScan Therapeutics Announces Q1 2026 Financial Results, Phase 3 TSC-101 Trial Launch, and Pipeline Updates - Minichart
TScan Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
TScan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
TScan Therapeutics, Inc. 1Q 2026: Revenue $982K, EPS $(0.22) — 10-Q Summary - TradingView
TScan Therapeutics Reports $175.3 Million in Cash Reserves, Funding Operations Into Second Half of 2028 - geneonline.com
TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TScan Therapeutics (NASDAQ: TCRX) narrows Q1 2026 loss as R&D declines and cash runway extends - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) narrows Q1 loss, plans Phase 3 - Stock Titan
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Is TScan Therapeutics (TCRX) stock worth taking a position in - newser.com
TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
TScan Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
TScan brings post-transplant cancer relapse research to Boston meeting - Stock Titan
TCRX Financials: Income Statement, Balance Sheet & Cash Flow | Tscan Therapeutics, Inc. - Stock Titan
Is institutional money buying TScan Therapeutics (TCRX) stock | Q4 2025: Profit Exceeds ViewsGuidance Update - Newser
LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TScan Therapeutics (NASDAQ: TCRX) seeks big boost in authorized shares at 2026 meeting - Stock Titan
[ARS] TScan Therapeutics, Inc. SEC Filing - Stock Titan
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TCRX: TCR T cell therapy shows >50% relapse reduction in AML/MDS, pivotal trial starts mid-2024 - TradingView
TCRX: TCR T cell therapy halves relapse rates in AML/MDS, with pivotal trial and expansion planned - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Analysts - MarketBeat
H.C. Wainwright reiterates Buy on Tscan stock, $7 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Tscan stock, $7 target - Investing.com
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Sahm
TScan Therapeutics (NASDAQ: TCRX) seeks approval to double authorized shares to 600M - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3%Here's What Happened - MarketBeat
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tscan Therapeutics Inc-Aktie (TCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):